Issue 3.23
As biopharma pipelines transition away from traditional, blockbuster-style products and toward highly targeted, complex modalities, the industry’s approach to investing into bioprocessing is shifting...
Issue 3.22
Bioprocessing is undergoing a transformation as various technological and process advancements help to improve yields, efficiency, and safety for drug developers and manufacturers...
Issue 3.21
Peptide therapeutics have the potential to become blockbusters on a scale that was previously seen within the monoclonal antibody space thanks to their effectiveness and biocompatibility...
Issue 3.20
Oral drug products have helped improve the lives of many patients, offering treatment in a convenient and easy to manage way; however, if the finished drug is unpalatable,…
Issue 3.19
The biopharmaceutical industry is moving away from the traditional blockbuster drug model, where facilities manufactured vast quantities of a single product, toward more personalized, highly targeted therapies and…
BIO International 2026
Drug development is shifting away from the traditional, legacy small-molecule pipelines and focusing on increasingly complex products that require greater technical acumen and specialized equipment, reveals Mark DaFonseca,…
Issue 3.18
The global bio/pharmaceutical outsourcing industry is experiencing a paradigm shift driven by macroeconomic pressures, changing regulatory paradigms, and the rise of asset-light virtual biotechnology firms…
Issue 3.17
The bio/pharmaceutical industry is in the midst of disruptive evolution thanks to an influx of niche modalities in development pipelines and increasing adoption of innovative, digital technologies that…
CPHI Americas 2026
The corporate landscape for pharmaceutical networking has traditionally been defined through the exhibition format, with hallways of expansive vendor booths designed primarily for product discovery...
Issue 3.16
Pharmaceutical excipients are considered an essential part of modern drug formulation. Comprising approximately 50–90% of the finished product, excipients ensure that limitations of the API, such as poor…
Issue 3.15
Generic and biosimilar drugs are vitally important for healthcare systems around the world and are increasingly in demand from patients thanks to their affordability when compared with the…
Issue 3.14
As the modern drug development pipeline becomes ever more saturated with complex molecules and targets shift toward ‘undruggable’ protein–protein interfaces, formulators are facing a solubility crisis that traditional…
